奶奶疗法

2023年5月2日

由马克特里5月2日,2023年东京阿斯特拉制药公司是购买新泽西的帕西帕尼Iveric生物为59亿美元。Iveric生物集中在眼科疾病,阿斯特拉的五个重点领域,失明和再生。作为交易的一部分,阿斯特拉拿起Iveric生物的avacincaptad pegol (ACP),品牌作为Zimura,由FDA审查地理萎缩(GA)二级年龄相关性黄斑变性(AMD)。公司的目标操作日期8月19日,2023年。ACP C5抑制剂的一个补充,该公司说,“拥有巨大的潜力来交付价值很大,服务水平低下的病人。“药物达到其主要疗效端点,减少通用航空发展的速度,在两个关键的临床试验。FDA也获得突破疗法的名称。收购还将提供阿斯特拉“ophthalmology-focused的基础功能,包括一个熟练的商业团队,广泛的眼科专家,网络医疗机构建立联系,和基础设施来支持联合眼科业务在未来。“我们很高兴与Iveric生物达成协议,公司研发的特殊专长的创新疗法在眼科领域。Iveric生物有前途的项目包括avacincaptad pegol,地理的重要项目,年龄相关性黄斑变性萎缩,和能力在整个价值链在眼科领域。我们相信,这次收购将使我们能够提供更大的价值眼部疾病高危患者失明,”阿斯特拉Naoki冈,总裁兼首席执行官,在一份声明中说。 This marks the fifth major overseas takeout by Astellas since 2019 as it works to bolster its pipeline as its main drivers lose patent protection, particularly its prostate cancer drug Xtandi. In 2019, Astellas picked up U.S. biotech Xyphos Biosciences for $665 million and Audentes Therapeutics for approximately $3 billion. It acquired Nanna Therapeutics for $15 million in April 2020 followed by Iota Biosciences for $128 million in October 2020. In a note to investors, Jefferies analysts said the Iveric deal “is mainly about a soon-to-be approved asset and seems less likely to generate impairment losses.” There is a possibility of real competition in the GA market. Apellis Pharmaceuticals received FDA approval for Syfovre in February. Other companies developing therapeutics for the condition include AstraZeneca, Johnson & Johnson, Novartis and Roche. It appears that Iveric Bio is likely to be the first competitor to Syfovre if approved by August. Geographic atrophy is a chronic progressive degeneration of the macula, part of late-stage age-related macular degeneration. It affects more than 8 million people globally, or about 20% of all people with AMD, according to the American Academy of Ophthalmology. Astellas believes that ACP with fezolinetant and PADCEV will strengthen its portfolio to compensate for future Xtandi sales drops due to patent expiration in 2027. Iveric was in the process of ramping up its sales team for ACP, with 120 people, including 50 to 70 field sales representatives. ACP is also in mid-stage clinical trials for autosomal recessive Stargardt disease. The company also has a preclinical asset, IC-500, an HtrA1 inhibitor, being developed for GA. Iveric’s AAV gene therapy pipeline, still in the research and preclinical stages, includes mini-CEP290 for Leber congenital amaurosis type 10, mini-ABCA4 for autosomal recessive Stargardt disease, and mini-USH2A for Usher syndrome type 2A. In addition to Blindness & Regeneration, Astellas’ four other Primary Focus Areas include Genetic Regulation, Immuno-Oncology, Mitochondria, and Targeted Protein Degradation. The company indicates vision loss caused by diseases of the eye presents a market of more than 160 people globally, many of which have no effective treatments. Its own lead program for GA and Stargardt disease is ASP7317. ASP2020, a universal donor cell-derived program, is now in the company’s pipeline. In addition, its Prograf is a prominent drug in the transplantation field. Its pipeline includes drugs for GA, glaucoma, retinitis pigmentosa, Dry AMD, optic neuropathy, corneal dystrophy and vascular disease. “The opportunity to create a world-class entity with the ophthalmology expertise and capabilities of Iveric Bio and the global reach and resources of Astellas is unique and has the potential to benefit patients worldwide suffering from blinding retinal diseases, including GA,” Pravin U. Dugel, president of Iveric Bio said in a statement. Both companies declined to provide additional information related to the deal. About the Author